Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 6/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 6/20 | 0.47 |
| ▸ | ATR | Q13535 | 11/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | IDH2 | P48735 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26986513 | 0.81 | CYP4F2 (0.48) | CYP4F2CYP4A11ATR | |
| SCHEMBL19732434 | 0.81 | ATR (0.54) | CYP4F2CYP4A11ATR | |
| SCHEMBL26986688 | 0.79 | CYP4F2 (0.46) | CYP4F2CYP4A11ATR | |
| SCHEMBL22954588 | 0.79 | CYP4F2 (0.66) | CYP4F2CYP4A11ATR | |
| SCHEMBL13734367 | 0.77 | CYP4F2 (0.53) | CYP4F2CYP4A11ATR | |
| SCHEMBL26986543 | 0.77 | CYP4F2 (0.45) | CYP4F2CYP4A11ATR | |
| SCHEMBL9977747 | 0.76 | CYP4F2 (0.52) | CYP4F2CYP4A11ATR | |
| SCHEMBL9977842 | 0.76 | CYP4F2 (0.54) | CYP4F2CYP4A11ATR | |
| SCHEMBL16589766 | 0.76 | CYP4F2 (0.48) | CYP4F2CYP4A11ATR | |
| SCHEMBL17429281 | 0.75 | ATR (0.36) | CYP4F2CYP4A11ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-24 | — | — | US | disclosed |
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-24 | — | — | US | disclosed |
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-24 | — | — | US | disclosed |
| EP-2653469-A1 | PYRAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012081692-A1 | PYRAZOLE DERIVATIVE | 大正製薬株式会社 (JP) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | HCRTR1, HCRTR2, NPY4R | CYP4F2 2278/4885CYP4A11 1266/4885ATR 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.